Biochemical characterization of the GM2 gangliosidosis B1 variant
- PMID: 15264019
- DOI: 10.1590/s0100-879x2004000600001
Biochemical characterization of the GM2 gangliosidosis B1 variant
Abstract
The deficiency of the A isoenzyme of beta-hexosaminidase (Hex) produced by different mutations of the gene that codes for the alpha subunit (Tay-Sachs disease) has two variants with enzymological differences: the B variant consists of the absence of Hex A isoenzyme and the B1 variant produces an inactive Hex A isoenzyme for the hydrolysis of the GM2 ganglioside and synthetic substrates with negative charge. In contrast to the early childhood form of the B variant, the B1 variant appears at a later clinical stage (3 to 7 years of age) with neurodegenerative symptoms leading to the death of the patient in the second decade of life. The most frequent mutation responsible for the GM2 gangliosidosis B1 variant is R178H, which has a widespread geographic and ethnic distribution. The highest incidence has been described in Portugal, which has been suggested as the point of origin of this mutation. Biochemical characterization of this lysosomal disease is carried out using negatively charged synthetic alpha subunit-specific sulfated substrates, since Hex A isoenzyme heat-inactivation assays are not applicable. However, the determination of the apparent activation energy of Hex using the neutral substrate 3,3'-dichlorophenolsulfonphthaleinyl N-acetyl-beta-D-glucosaminide, may offer a valid alternative. The presence of an alpha subunit in the alphabeta heterodimer Hex A means that its activation energy (41.8 kJ/mol) is significantly lower than that of the betabeta homodimer Hex B (75.1 kJ/mol); however, as mutation inactivates the alpha subunit, the Hex A of the B1 variant presents an activation energy that is similar to that of the Hex B isoenzyme.
Similar articles
-
Thermodynamic determination of plasma and leukocyte beta-hexosaminidase isoenzymes in homozygote and heterozygote carriers for the GM2 gangliosidosis B1 variant.Am J Clin Pathol. 2003 May;119(5):684-8. doi: 10.1309/AHTK-LPRK-B4NW-0X5M. Am J Clin Pathol. 2003. PMID: 12760286
-
Thermodynamic characterisation of the mutated isoenzyme A of beta-N-acetylhexosaminidase in GM2-gangliosidosis B1 variant.Clin Chim Acta. 1999 Jul;285(1-2):45-51. doi: 10.1016/s0009-8981(99)00086-8. Clin Chim Acta. 1999. PMID: 10481922
-
A Pro504 --> Ser substitution in the beta-subunit of beta-hexosaminidase A inhibits alpha-subunit hydrolysis of GM2 ganglioside, resulting in chronic Sandhoff disease.J Biol Chem. 1998 Aug 14;273(33):21386-92. doi: 10.1074/jbc.273.33.21386. J Biol Chem. 1998. PMID: 9694901
-
Biochemical and molecular aspects of late-onset GM2-gangliosidosis: B1 variant as a prototype.Dev Neurosci. 1991;13(4-5):288-94. doi: 10.1159/000112175. Dev Neurosci. 1991. PMID: 1840099 Review.
-
The GM2 gangliosidoses databases: allelic variation at the HEXA, HEXB, and GM2A gene loci.Genet Med. 2000 Nov-Dec;2(6):319-27. doi: 10.1097/00125817-200011000-00003. Genet Med. 2000. PMID: 11339652 Review.
Cited by
-
Microglia-Specific Expression of HEXA and HEXB Leads to Poor Prognosis in Glioblastoma Patients.Front Oncol. 2021 Aug 4;11:685893. doi: 10.3389/fonc.2021.685893. eCollection 2021. Front Oncol. 2021. PMID: 34422641 Free PMC article.
-
Screening for Tay-Sachs disease carriers by full-exon sequencing with novel variant interpretation outperforms enzyme testing in a pan-ethnic cohort.Mol Genet Genomic Med. 2019 Aug;7(8):e836. doi: 10.1002/mgg3.836. Epub 2019 Jul 10. Mol Genet Genomic Med. 2019. PMID: 31293106 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources